July 15, 2026 —
Voyager Therapeutics presented six-month good laboratory practice toxicology data for VY1706, its investigational BBB-crossing AAV gene therapy targeting tau for Alzheimer’s disease, at the Alzheimer’s Association International Conference.
The data showed that VY1706 was well tolerated in non-human primates following a single intravenous dose and produced sustained reductions in tau-related biomarkers for up to six months. Voyager reported up to 75% lowering of MAPT mRNA and tau protein in key Alzheimer’s disease-relevant brain regions.
VY1706 is designed to reduce both intracellular and extracellular tau, a protein associated with neurodegeneration and cognitive decline in Alzheimer’s disease. The therapy uses a vectorized siRNA targeting MAPT mRNA, encapsulated in Voyager’s TRACER™ AAV capsid for systemic delivery to the brain.
The TRACER capsid is designed to cross the blood-brain barrier after intravenous administration by leveraging ALPL, a conserved endothelial receptor expressed in brain vasculature. Voyager said ALPL-mediated transport supports the potential for cross-species translatability.
In the three- and six-month GLP toxicology study, VY1706 demonstrated a favorable tolerability profile in non-human primates. No adverse clinical pathology or histopathological findings were observed in the central nervous system, dorsal root ganglia, or peripheral organs, including the liver, up to the highest tested dose of 5 × 10¹³ vg/kg.
The data also showed broad, durable, and dose-dependent CNS delivery after a single intravenous dose. In addition to tau lowering, Voyager highlighted liver de-targeting as a potentially important feature, given that liver exposure can contribute to safety concerns in systemically administered gene therapies.
Voyager received FDA Investigational New Drug clearance for VY1706 in June 2026, enabling initiation of a clinical trial in adults with early Alzheimer’s disease. The company expects dosing to begin in the second half of 2026.
VY1706 is the first tau-targeted gene therapy with an IND cleared by the FDA, according to Voyager. The program reflects growing interest in using engineered AAV capsids and vectorized RNA silencing approaches to address neurological diseases that require broad CNS delivery.
If successfully translated into humans, VY1706 could represent a differentiated approach to Alzheimer’s disease by targeting tau production directly through a one-time intravenous genetic medicine. The upcoming clinical trial will be important for evaluating whether the preclinical safety, delivery, and tau-lowering profile can translate into patients with early disease.
